What Does Wall Street Think About Beam Therapeutics (BEAM)?

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best biotech stocks with high potential. H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Beam Therapeutics Inc. (NASDAQ:BEAM) on September 15, retaining the price target of $80. Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy? The analyst supported the optimistic rating with the company’s strong momentum in its in vivo and ex vivo base editing programs. Similarly, in a report released on September 10, Kostas Bilio ...